How does ketamine-assisted therapy work for depression?

Ketamine-assisted therapy for depression operates through a convergence of neurobiological and psychological mechanisms that the retrieved sources touch on only partially — the pharmacology of ketamine specifically is not well represented in the library here — but the broader framework of how altered states interact with the depressed psyche is worth tracing carefully.

The most established neurobiological account centers on the default mode network (DMN). The DMN is active during self-referential thought, rumination, and the kind of recursive negative self-narrative that characterizes depression. As Carhart-Harris (2014) demonstrated with classical psychedelics, and as the broader literature on dissociative agents like ketamine extends, substances that suppress or disrupt DMN activity appear to produce therapeutic benefit precisely by interrupting this self-reinforcing loop. Jung had a name for the psychological correlate of this disruption: abaissement du niveau mental, the depotentiation of conscious personality. As he observed in The Practice of Psychotherapy (1954), this loosening of the ego's grip — whether induced by fever, religious fervor, or pharmacological means — carries both risk and the possibility of genuine reorganization.

This critical state, where the conscious mind is liable to be submerged at any moment in the unconscious, is akin to the "loss of soul" that frequently attacks primitives. It is a sudden abaissement du niveau mental, a slackening of the conscious tension.

The ego's temporary surrender is not, in this reading, a side effect to be minimized — it is the mechanism. Mahr (2020) makes this point directly in the context of psychedelic therapy: "By altering perception and the typical brain pathways that establish the sense of personal identity, psychedelic drugs disrupt ego function. Overwhelmed by powerful imagery and an altered sense of personhood, the ego must 'give up,' as it were, and acknowledge its own powerlessness. This surrender allows for a receptivity to deeper emotions and thoughts that transcend the ego's limited view of the world." Ketamine, though pharmacologically distinct from classical psychedelics (it is a dissociative NMDA receptor antagonist rather than a serotonergic agent), produces a structurally similar loosening of ego-boundaries, and the therapeutic logic is analogous.

The interoceptive dimension matters here as well. Depression is consistently associated with interoceptive dysregulation — a disrupted capacity to detect, appraise, and respond to the body's internal signals. The insula, which serves as the brain's primary interoceptive hub and a key node in the salience network, shows abnormal activity and connectivity in major depressive disorder. Functional MRI studies link symptom improvement in depression to normalizations of insula activity (Khoury et al., 2018). Ketamine's rapid antidepressant effect — often appearing within hours, long before any conventional antidepressant takes hold — may partly reflect its capacity to reset these interoceptive prediction loops, allowing the brain to update its body-budget calculations rather than continuing to generate the same depressive predictions.

Barrett (2017) offers a useful frame: the brain is fundamentally a prediction machine, and depression can be understood as a state in which the interoceptive network is locked into generating unpleasant, low-arousal predictions that then become self-confirming. Ketamine disrupts this lock. The question of what the person does with that disruption — how the window of neuroplasticity opened by the drug is used — is where the "therapy" in ketamine-assisted therapy becomes essential. Research protocols consistently emphasize preparation and integration precisely because the pharmacological opening is not itself the work; it is the condition of possibility for the work.

There is a soul-level question underneath the neurobiological one, and it is worth naming. Depression often carries what the tradition would recognize as a nigredo quality — the alchemical blackening that Hillman (2010) describes as dissolving "whatever we rely upon as real and dear," breaking the paradigm, making possible what could not otherwise shift. The danger of framing ketamine purely as a rapid antidepressant is that it can be recruited into the pneumatic logic — if I feel better enough, I will not have to suffer — rather than allowed to do the deeper work of disclosure. The soul's speech in the failure of its usual strategies is what depth work actually listens for. Ketamine can open that listening, or it can be used to close it faster.

  • nigredo — the alchemical blackening as psychological initiation
  • abaissement du niveau mental — Jung's term for the depotentiation of conscious personality
  • James Hillman — portrait of the founder of archetypal psychology
  • interoception — the body's sense of its own internal state and its role in emotion and psychopathology

Sources Cited

  • Jung, C.G., 1954, Collected Works Volume 16: The Practice of Psychotherapy
  • Mahr, Greg, 2020, Psychedelic Drugs and Jungian Therapy
  • Hillman, James, 2010, Alchemical Psychology
  • Khoury, Nayla M., 2018, Interoception in Psychiatric Disorders
  • Barrett, Lisa Feldman, 2017, How Emotions Are Made
  • Carhart-Harris, Robin, 2014, The Entropic Brain